Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2558–2561. doi: 10.1128/aac.40.11.2558

Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.

J Tankovic 1, F Mahjoubi 1, P Courvalin 1, J Duval 1, R Leclerco 1
PMCID: PMC163575  PMID: 8913464

Abstract

We have analyzed the development of fluoroquinolone resistance between 1986 and 1993 among clinical isolates of Enterococcus faecalis from a French hospital. One hundred randomly selected isolates per year were screened for resistance to ciprofloxacin (MIC > 2 micrograms/ml) and for high-level resistance to gentamicin (MIC > 1,000 micrograms/ml). The percentages of ciprofloxacin-resistant strains for these years were as follows: 1986, 0; 1987, 1; 1988 to 1989, 2; 1990, 6; 1991, 16; 1992, 24; and 1993, 14. Eighty-three percent of the ciprofloxacin-resistant isolates were coresistant to high levels of gentamicin. Forty-eight high-level gentamicin-resistant E. faecalis strains, which were resistant (24 strains) or susceptible (24 strains) to ciprofloxacin, were examined by pulsed-field gel electrophoresis (PFGE) of SmaI-digested total DNA. Numerous PFGE types were observed among the ciprofloxacin-susceptible isolates, whereas one type was largely predominant among the ciprofloxacin-resistant strains, which suggests that the increase in fluoroquinolone resistance was due to the spread of a single clone. A 241-bp fragment of gyrA, corresponding to the quinolone resistance-determining region, was amplified and sequenced for seven ciprofloxacin-resistant isolates. Six strains had high levels of resistance (MICs, 32 to 64 micrograms/ml) and had a mutation at position 83 (Escherichia coli coordinates) from Ser to Arg (three strains) or to Ile (two strains) or at position 87 from Glu to Gly (one strain), whereas the low-level-resistant isolate (MIC, 8 micrograms/ml) had no mutations.

Full Text

The Full Text of this article is available as a PDF (234.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baddour L. M., Hicks D. V., Tayidi M. M., Roberts S. K., Walker E., Smith R. J., Sweitzer D. S., Herrington J. A., Painter B. G. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital. Microb Drug Resist. 1995 Fall;1(3):219–222. doi: 10.1089/mdr.1995.1.219. [DOI] [PubMed] [Google Scholar]
  2. Eliopoulos G. M. Increasing problems in the therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):409–412. doi: 10.1007/BF01967433. [DOI] [PubMed] [Google Scholar]
  3. Handwerger S., Raucher B., Altarac D., Monka J., Marchione S., Singh K. V., Murray B. E., Wolff J., Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993 Jun;16(6):750–755. doi: 10.1093/clind/16.6.750. [DOI] [PubMed] [Google Scholar]
  4. Jacob A. E., Hobbs S. J. Conjugal transfer of plasmid-borne multiple antibiotic resistance in Streptococcus faecalis var. zymogenes. J Bacteriol. 1974 Feb;117(2):360–372. doi: 10.1128/jb.117.2.360-372.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones R. N., Barry A. L. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990 Feb;34(2):306–313. doi: 10.1128/aac.34.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaatz G. W., Seo S. M., Ruble C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May;37(5):1086–1094. doi: 10.1128/aac.37.5.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Korten V., Huang W. M., Murray B. E. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother. 1994 Sep;38(9):2091–2094. doi: 10.1128/aac.38.9.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Midgley M. Characteristics of an ethidium efflux system in Enterococcus hirae. FEMS Microbiol Lett. 1994 Jul 1;120(1-2):119–123. doi: 10.1111/j.1574-6968.1994.tb07017.x. [DOI] [PubMed] [Google Scholar]
  9. Murray B. E., Singh K. V., Heath J. D., Sharma B. R., Weinstock G. M. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol. 1990 Sep;28(9):2059–2063. doi: 10.1128/jcm.28.9.2059-2063.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Murray B. E. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. doi: 10.1128/cmr.3.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nakanishi N., Yoshida S., Wakebe H., Inoue M., Mitsuhashi S. Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Jun;35(6):1053–1059. doi: 10.1128/aac.35.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sahm D. F., Koburov G. T. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989 Jan;33(1):71–77. doi: 10.1128/aac.33.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schaberg D. R., Dillon W. I., Terpenning M. S., Robinson K. A., Bradley S. F., Kauffman C. A. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2533–2535. doi: 10.1128/aac.36.11.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tankovic J., Duval J., Courvalin P. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus. FEMS Immunol Med Microbiol. 1994 Jun;9(1):35–39. doi: 10.1111/j.1574-695X.1994.tb00471.x. [DOI] [PubMed] [Google Scholar]
  18. Tankovic J., Perichon B., Duval J., Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996 Nov;40(11):2505–2510. doi: 10.1128/aac.40.11.2505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tenover F. C., Arbeit R. D., Goering R. V., Mickelsen P. A., Murray B. E., Persing D. H., Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995 Sep;33(9):2233–2239. doi: 10.1128/jcm.33.9.2233-2239.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES